1291 related articles for article (PubMed ID: 19363453)
1. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
3. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
Verbsky JW; White AJ
J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
[TBL] [Abstract][Full Text] [Related]
5. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
Nigrovic PA; Mannion M; Prince FH; Zeft A; Rabinovich CE; van Rossum MA; Cortis E; Pardeo M; Miettunen PM; Janow G; Birmingham J; Eggebeen A; Janssen E; Shulman AI; Son MB; Hong S; Jones K; Ilowite NT; Cron RQ; Higgins GC
Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
[TBL] [Abstract][Full Text] [Related]
6. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis.
Kimura Y; Fieldston E; Devries-Vandervlugt B; Li S; Imundo L
J Rheumatol; 2000 Aug; 27(8):2018-24. PubMed ID: 10955346
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
Swart JF; Barug D; Möhlmann M; Wulffraat NM
Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
[TBL] [Abstract][Full Text] [Related]
9. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA).
Ohlsson V; Baildam E; Foster H; Jandial S; Pain C; Strike H; Ramanan AV
Rheumatology (Oxford); 2008 Apr; 47(4):555-6. PubMed ID: 18321945
[No Abstract] [Full Text] [Related]
10. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.
Cohen SB; Strand V; Aguilar D; Ofman JJ
Rheumatology (Oxford); 2004 Jun; 43(6):704-11. PubMed ID: 14997006
[TBL] [Abstract][Full Text] [Related]
11. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
12. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
[TBL] [Abstract][Full Text] [Related]
13. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
[TBL] [Abstract][Full Text] [Related]
14. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.
Bruck N; Suttorp M; Kabus M; Heubner G; Gahr M; Pessler F
J Clin Rheumatol; 2011 Jan; 17(1):23-7. PubMed ID: 21169853
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M
Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
[TBL] [Abstract][Full Text] [Related]
17. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
Woo P; Southwood TR; Prieur AM; Doré CJ; Grainger J; David J; Ryder C; Hasson N; Hall A; Lemelle I
Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
[TBL] [Abstract][Full Text] [Related]
19. A case of macrophage activation syndrome successfully treated with anakinra.
Kelly A; Ramanan AV
Nat Clin Pract Rheumatol; 2008 Nov; 4(11):615-20. PubMed ID: 18825135
[TBL] [Abstract][Full Text] [Related]
20. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.
Woo P
Ann Rheum Dis; 2008 Mar; 67(3):281-2. PubMed ID: 18292104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
